A First-in-Human Study for BAF312: A Two Parts, Single Center, Randomized, Double-Blind, Placebo-Controlled Ascending Single Dose Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral BAF312 in Healthy Volunteers

Trial Profile

A First-in-Human Study for BAF312: A Two Parts, Single Center, Randomized, Double-Blind, Placebo-Controlled Ascending Single Dose Study to Explore the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral BAF312 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Apr 2010

At a glance

  • Drugs Siponimod (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 15 Apr 2010 Results were presented at AAN 2010.
    • 28 Nov 2008 Status changed from recruiting to completed.
    • 12 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top